Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2011-07-05
2011-07-05
Wen, Sharon (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100
Reexamination Certificate
active
07972599
ABSTRACT:
Follistatin-like protein (FSTL-1) is a secreted glycoprotein of unknown function, first isolated from mouse osteoblastic cells as a transforming growth factor-β1-inducible gene. The inventors have discovered that FSTL-1 is a proinflammatory mediator. As such, the invention provides for composition and methods of using agents that bind to FSTL-1 to modulate various types of inflammation (e.g., autoimmune diseases). Inhibitors and antagonists of FSTL-1, particularly antibodies or antibody fragments, may be used to treat conditions related to inflammation, such as arthritis. In addition, the inventors have discovered that FSTL-1 has a role in the Th17 pathway. Accordingly, the invention provides for compositions and methods of using agents which bind to FSTL-1 to modulate the generation of Th17 cells. Such agents are useful for delaying development of and treating diseases associated with undesired production of Th17 cells, such as autoimmune diseases. Furthermore, since FSTL-1 is a proinflammatory mediator with a role in cancer, the invention provides for compositions and methods of using a pharmaceutical composition of FSTL-1 to delay development of or treat cancer.
REFERENCES:
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5605690 (1997-02-01), Jacobs et al.
patent: 6410232 (2002-06-01), Holtzman
patent: 2005/0202421 (2005-09-01), Hirsch et al.
patent: WO-94/06476 (1994-03-01), None
patent: WO-2004/018522 (2004-03-01), None
patent: WO-2004/018522 (2004-03-01), None
patent: WO-2005/005471 (2005-01-01), None
patent: WO-2005/005471 (2005-01-01), None
patent: WO-2005/032328 (2005-04-01), None
patent: WO-2005/032328 (2005-04-01), None
The Merck Manuals Online Medical Library, [online]. Whitehouse Station, NJ: Merck Research Laboratories, 2006-2007. [retrieved on Nov. 19, 2007]. Retrieved from the Internet: < URL: http://www.merck.com/mmpe/print/sec06/ch068/ch068a.html>. Sepsis and Septic Shock. see pp. 1-5.
Standen et al. (N Engl J Med 2000, 343:447-448).
Aggarwal, S. et al. (Jan. 17, 2003). “Interleukin-23 Promotes a Distinct CD4 T Cell Activation State Characterized by the Production of Interleukin-17,”Journal of Biological Chemistry278(3):1910-1914.
Bettelli, E. et al. (May 11, 2006). “Reciprocal Developmental Pathways for the Generation of Pathogenic Effector TH17 and Regulatory T Cells,”Nature441:235-238.
Cole, S.P.C. et al. (1985). “The EBV-Hybridoma Technique and Its Application to Human Lung Cancer,”in Monoclonal Antibodies and Cancer Therapy, pp. 77-96.
Constantinescu, C.S. et al. (1998). “Antibodies Against IL-12 Prevent Superantigen-Induced and Spontaneous Relapses of Experimental Autoimmune Encephalomyelitis,”J. Immunol. 161:5097-5104.
Cote, R.J. et al. (Apr. 1983). “Generation of Human Monoclonal Antibodies Reactive with Cellular Antigens,”Proc. Natl. Acad. Sci. USA80:2026-2030.
Ehara, Y. et al. (Nov.-Dec. 2004). “Follistatin-Related Protein Gene (FRP) is Expressed in the Synovial Tissues of Rheumatoid Arthritis, But its Polymorphisms are not Associated with Genetic Susceptibility,”Clin. Exp. Rheumatol. 22:707-712.
GenBank Accession No. BC000055 updated Jul. 15, 2006, located at <http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&id=33990756>, last visited on Aug. 8, 2007, four pages.
GenBank Accession No. BC028921 updated Jul. 15, 2006, located at <http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&id=208100326>, last visited Aug. 8, 2007, three pages.
Hambrock, H.O. et al. (Mar. 19, 2004, e-pub. Dec. 30, 2003). “Structural Characterization of TSC-36/Flik: Analysis of Two Charge Isoforms,”Journal of Biological Chemistry279(12):11727-11735.
Hardy, S. et al. (Mar. 1997). “Construction of Adenovirus Vectors Through Cre-loxRecombination,”Journal of Virology71(3):1842-1849.
Honorati, M.C. et al. (2001). “High in vivo Expression of Interleukin-17 Receptor in Synovial Endothelial Cells and Chondrocytes From Arthritis Patients,”Rheumatology40:522-527.
Hwang, S.Y. et al. (2004). “IL-17 Induces Production of IL-6 and IL-8 in Rheumatoid Arthritis Synovial Fibroblasts via NF-κB- and PI3-Kinase/Akt-Dependent Pathways,”Arthritis Res. Ther. 6(2):R120-R128.
International Search Report mailed Nov. 15, 2007, for PCT Application No. PCT/US2007/064441, filed Mar. 20, 2007, eight pages.
Ivanov, I.I. et al. (Sep. 22, 2006). “The Orphan Nuclear Receptor RORγt Directs the Differentiation Program of Proinflammatory IL-17+T Helper Cells,”Cell126:1121-1133.
Johnston, I.M.P. et al. (Nov. 9, 2000). “Regulation of a Multigenic Invasion Programme by the Transcription Factor, AP-1: Re-Expression of a Down-Regulated Gene, TSC-36, Inhibits Invasion,”Oncogene19:5348-5358.
Kawabata, D. et al. (Feb. 2004). “Ameliorative Effects of Follistatin-Related Protein/TSC-36/FSTL1 on Joint Inflammation in a Mouse Model of Arthritis,”Arth. Rheum. 50(2):660-668.
Kim, H.-R. (2007). “Up-Regulation of IL-23p19 Expression in Rheumatoid Arthritis Synovial Fibroblasts by IL-17 Through PI3-Kinase-, NF-κB- and p38 MAPK-Dependent Signalling Pathways,”Rheumatology46:57-64.
Kohler, G. et al. (Aug. 7, 1975). “Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity,”Nature256:495-497.
Kolls, J.K. et al. (Oct. 2004). “Interleukin-17 Family Members and Inflammation,”Immunity21:467-476.
Kotake, S. et al. (May 1999). “IL-17 in Synovial Fluids from Patients with Rheumatoid Arthritis is a Potent Stimulator of Osteoclastogenesis,”J. Clin. Invest. 103(9):1345-1352.
Kozbor, D. et al. (1983). “The Production of Monoclonal Antibodies from Human Lymphocytes,”Immunology Today4(3):72-79.
Leonard, J.P. (Jan. 1, 1995). “Prevention of Experimental Autoimmune Encephalomyelitis by Antibodies Against Interleukin 12,”J. Exp. Med. 181(1):381-386.
Lubberts, E. et al. (2001). “IL-1-Independent Role of IL-17 in Synovial Inflammation and Joint Destruction During Collagen-Induced Arthritis,”J. Immunol. 167:1004-1013.
Mashimo, J. et al. (Feb. 26, 1997). “Decrease in the Expression of a Novel TGF β1-Inducible andras-Recision Gene, TSC-36, in Human Cancer Cells,”Cancer Lett.113(1,2):213-219.
Miyamae, T. et al. (May 2005). “Over-Expression of Follistatin-Like Protein Exacerbates Collagen Induced Arthritis,”Molecular Therapy11(1-Suppl.1):S264, Abstract No. 682.
Miyamae, T. et al. (Oct. 1, 2006). “Follistatin-Like Protein-1 Is a Novel Proimflammatory Molecule,”Journal of Immunolgy177(7):4758-4762.
Mohan, A. et al. (Oct. 2001). “Effect of Cytokines and Growth Factors on the Secretion of Inhibin A, Activin A and Follistatin by Term Placental Villous Trophoblasts in Culture,”Eur. J. Endocrinol. 145:505-511.
Morrison, S.L. et al. (Nov. 1984). “Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains with Human Constant Region Domains,”Proc. Natl. Acad. Sci. 81:6851-6855.
Nakae, S. et al. (2003). “Suppression of Immune Induction of Collagen-Induced Arthritis in IL-17-Deficient Mice,”J. Immunol. 171:6173-6177.
Neuberger, M.S. et al. (Dec. 13, 1984). “Recombinant Antibodies Possessing Novel Effector Functions,”Nature312:604-608.
Ohashi, T. et al. (Nov. 1997). “TSC-36 (Follistatin-Related Polypeptide) Gene Expression in Estrogen Receptor Positive Osteoblastic Cell Line, CDO7F,”Calcif. Tissue Int. 61:400-403.
Okabayashi, K. et al. (Jan. 8, 1999). “cDNA Cloning and Distribution of theXenopusFollistatin-Related Protein,”Biochem. Biophys. Res. Commun. 254(1):42-48.
Oppmann, B. et al. (Nov. 2000). “Novel p19 Protein Engages IL-12p40 to Form a Cytokine, IL-23, with Biological Activities Similar as Well as Distinct from IL-12,”Immunity13:715-725.
Overbergh, L. et al. (Mar. 2003). “The Use of Real-Time Reverse Transcriptase PCR for the Qu
Hirsch Raphael
Marinov Anthony D.
Wilson David C.
Baker & Botts LLP
University of Pittsburgh of the Commonwealth System of Higher Ed
Wen Sharon
LandOfFree
Immunomodulation of inflammatory conditions utilizing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunomodulation of inflammatory conditions utilizing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunomodulation of inflammatory conditions utilizing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2716074